Blog Post
Manifest added a blog post.
3:33 PM
The Street is wrecked over the Actavis integration and Copaxone competition. Teva Pharma (TEVA) is a gorilla and the 3-5 year outlook is pretty good. The Value Line low total return forecast is approximately 15% and TEVA [more]